Search Results

Bausch Health, Canada Inc. today announced the first public drug plan listings for Pr UCERIS (budesonide) aerosol foam to treat mild to moderate distal ulcerative colitis in adults.

Novartis Pharmaceuticals Canada Inc. is pleased to announce a partnership with Clarius Mobile Health as part of a dedicated effort to aid in early detection of psoriatic arthritis in Canada.

Saladax Biomedical, Inc. is pleased to announce that Health Canada has approved Saladax’s 5-Fluorouracil Assay for sale in Canada in a rapid six days.

Novartis Pharmaceuticals Canada Inc. (Novartis) is pleased to announce that Health Canada has granted Cosentyx® (secukinumab) with a Notice of Compliance (NOC) for the treatment of adult patients with moderate to severe hidradenitis suppurativa (HS) (acne inversa) who have responded inadequately to conventional systemic hidradenitis suppurativa therapy – representing a safe and efficacious new treatment option for Canadians living with the condition.

Today, Pfizer Canada announced that Health Canada has granted a Notice of Compliance (NOC) for VELSIPITY™.

Bausch + Lomb Corporation, a leading global eye health company dedicated to helping people see better to live better, announced that Health Canada has approved the enVista® Envy™* full visual range intraocular lens.

AbbVie announced that Health Canada has approved QULIPTA for the prevention of migraine in adults who have at least four migraine days per month.

Entos Pharmaceuticals (Entos or the Company), a clinical-stage biotechnology company developing genetic medicines with its proprietary Fusogenix PLV nucleic acid delivery platform, and its partner, Aegis Life, Inc. (Aegis), today announced that Entos has received approval from Health Canada to initiate a phase 1/2 clinical trial (NCT06436911) evaluating Covigenix VAX-002, an investigational COVID-19 booster vaccine.